The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the likelihood that the person sitting in your clinic in front of you is half as healthy as the patient that clinical trial is very low and therefore they're not going to be as resilient which means a they probably can't tolerate the drug as well and b they don't have the physiologic reserve such that the delta between them and the untreated patient is likely to be far compressed
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.